Seeking Alpha
22 Jul 2026, 19:31 UTC · 2h ago
Summit Therapeutics: 'Buy' On Ivonescimab's November PDUFA And Impressive Partner Data
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
22 Jul 2026, 19:31 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
The FDA has accepted the Biologics License Application (BLA) for ivonescimab plus chemotherapy in EGFR-mutant NSCLC, with a PDUFA date set for November 14, 2026. — FDA acceptance and a firm PDUFA date create a concrete binary catalyst for potential commercialization and revenue generation.
+0.80Akeso's HARMONi-6 trial demonstrated that ivonescimab plus chemotherapy achieved a 34% reduction in the risk of death compared to tislelizumab plus chemotherapy in 1st-line NSCLC. — Strong clinical efficacy data against a comparator increases the likelihood of regulatory approval and market adoption.
+0.60Summit Therapeutics is expecting HARMONi-3 interim data to be released in the second half of 2026. — Additional phase 3 data serves as a secondary catalyst that could either validate or undermine the drug's broader market potential.
+0.40Continue reading
6 related stories
Search tags
The company faces ongoing risks related to cash burn and potential shareholder dilution. — Financial instability or the need for capital raises can depress share prices despite positive clinical progress.
-0.30Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
4h ago
